Go to Top
INVENTOR LOGIN

Details

Project TitleIn Vivo Imaging Of Tumor Infiltrating Leukocytes
Track Code2017-024
Short Description

A method of diagnosing cancerous tumors in patients with the use of radiolabeled ligands of leukocyte function-associated antigen-1 (LFA-1) receptor.

Abstract

LFA-1 receptor expression can be imaged using a novel radiolabeled small molecule that allows for quantification of leukocyte trafficking to tumors, in order to: characterize tumor infiltrating leukocytes to identify response, monitor response to immunotherapy, stage disease, detect residual disease after therapy, and to direct personalized medicine. A primary advantage of this non-invasive imaging radioligand is the sensitivity with which the radiopharmaceutical can detect the disease and its spread in the body.

 
Tagscancer immunotherapy, oncology, cancer therapy, monitoring, diagnostic
 
Posted DateAug 11, 2017 10:47 AM

Researcher

Name
Jeffrey Norenberg

Manager

Name
Jovan Heusser

Background

Immunotherapy of cancer is rapidly evolving, leading to the FDA approval of several new immunotherapies for various types of cancers. The current methods used to monitor leukocyte response to immunotherapies is limited to whole blood or biopsies from heterogeneous tumors. These invasive techniques do not reflect the dynamic and spatial information required to monitor immune responses to therapeutic interventions. According to the American Association for Cancer Research, analysis of tumor-infiltrating lymphocytes (TIL) has demonstrated the importance of tumor immune microenvironment and that the presence of cytotoxic CD8 T cells can predict overall survival in breast, lung, ovarian, melanoma, and colorectal cancer. The field of cancer immunotherapy is currently limited by the lack of non-invasive technologies capable of evaluating and monitoring leukocyte activation, recruitment, and trafficking of solid tumors. Thus, there is a current market need for non-invasive imaging of tumor infiltrating leukocytes to diagnose and treat cancers.

Technology Description

A researcher at the University of New Mexico has developed a method of diagnosing cancerous tumors in patients with the use of radiolabeled ligands of leukocyte function-associated antigen-1 (LFA-1) receptor. LFA-1 receptor expression can be imaged using a novel radiolabeled small molecule that allows for quantification of leukocyte trafficking to tumors, in order to: characterize tumor infiltrating leukocytes to identify response, monitor response to immunotherapy, stage disease, detect residual disease after therapy, and to direct personalized medicine. A primary advantage of this non-invasive imaging radioligand is the sensitivity with which the radiopharmaceutical can detect the disease and its spread in the body.

Advantages/Applications


  • in vivo non-invasive PET/SPECT imaging agent to quantify leukocyte activation, recruitment, and in vivo trafficking
  • Greater detection sensitivity
  • Ability to assess small and very large regions of interest: local, regional, and whole-body
  • Can be applied multiple times in the same patient
  • Applications in cancer immunotherapy, diagnosing and monitoring cancer therapy

INQUIRES

STC has filed intellectual property on this exciting new technology and is currently exploring commercialization options. If you are interested in information about this or other technologies, please contact Arlene Mirabal at amirabal@stc.unm.edu or 505-272-7886.